75 related articles for article (PubMed ID: 36200934)
1. Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production.
Essa MF; Abdellatif R; Elimam N; Ballourah W; Alsudairy R; Alkaiyat M; Alsultan A; Jastaniah W
Pediatr Hematol Oncol; 2022 Oct; 39(7):613-628. PubMed ID: 36200934
[TBL] [Abstract][Full Text] [Related]
2. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Leotta S; Markovic U; Duminuco A; Mulè A; Porretto F; Federico V; Gentile M; Pastore D; Nigro LL; Selleri C; Serio B; Calafiore V; Patti C; Mauro E; Vetro C; Maugeri C; Parisi M; Fiumara P; Parrinello L; Marino S; Scuderi G; Garibaldi B; Musso M; Renzo ND; Vigna E; Martino EA; Raimondo FD; Milone G
Ann Hematol; 2024 Apr; ():. PubMed ID: 38609726
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
Gu M; Xia Y; Zhang J; Tang Y; Xu W; Song H; Xu X
Cancer Med; 2023 Dec; 12(24):21978-21984. PubMed ID: 38063317
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation.
Sayyed A; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J; Pasic I
Transplant Cell Ther; 2024 May; 30(5):520.e1-520.e12. PubMed ID: 38462215
[TBL] [Abstract][Full Text] [Related]
6. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E; Zugmaier G; Agrawal V; Martínez-Sánchez P; Rifón Roca JJ; Cassaday RD; Böll B; Rijneveld A; Abdul-Hay M; Huguet F; Cluzeau T; Díaz MT; Vucinic V; González-Campos J; Rambaldi A; Schwartz S; Berthon C; Hernández-Rivas JM; Gordon PR; Brüggemann M; Hamidi A; Chen Y; Wong HL; Panwar B; Katlinskaya Y; Markovic A; Kantarjian H
Am J Hematol; 2024 Apr; 99(4):586-595. PubMed ID: 38317420
[TBL] [Abstract][Full Text] [Related]
7. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
Curran E; Stock W
Blood; 2019 Apr; 133(16):1715-1719. PubMed ID: 30796026
[TBL] [Abstract][Full Text] [Related]
8. Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zhai Y; Hong J; Wang J; Jiang Y; Wu W; Lv Y; Guo J; Tian L; Sun H; Li Y; Li C; Zhan H; Zhao Z
Expert Rev Hematol; 2024; 17(1-3):67-76. PubMed ID: 38135295
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
Zhou H; Wu X; Yang Z; Lu S; Zhang X; Yang X; Chen S; Wu D; Miao M
Invest New Drugs; 2024 Apr; ():. PubMed ID: 38662275
[TBL] [Abstract][Full Text] [Related]
10. Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.
Lu J; Zhou H; Zhou X; Yang Y; Tong L; Miao M; Yang X; Chen S
Cancer Med; 2024 Mar; 13(5):e7062. PubMed ID: 38491815
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Duminuco A; Markovic U; Parrinello NL; Lo Nigro L; Mauro E; Vetro C; Parisi M; Maugeri C; Fiumara PF; Milone G; Romano A; Di Raimondo F; Leotta S
Front Immunol; 2023; 14():1195734. PubMed ID: 37809082
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.
Kantarjian HM; Logan AC; Zaman F; Gökbuget N; Bargou RC; Zeng Y; Zugmaier G; Locatelli F
Ther Adv Hematol; 2023; 14():20406207231201454. PubMed ID: 37822571
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Fracchiolla NS; Sciumè M; Papayannidis C; Vitale A; Chiaretti S; Annunziata M; Giglio F; Salutari P; Forghieri F; Lazzarotto D; Lunghi M; Imovilli A; Scappini B; Bonifacio M; Dargenio M; Gurrieri C; Todisco E; Defina M; Del Principe MI; Zappasodi P; Cerrano M; Santoro L; Tagliaferri E; Barozzi E; De Roberto P; Canzi M; Buzzatti E; Sartor C; Passamonti F; Foà R; Curti A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760592
[TBL] [Abstract][Full Text] [Related]
14. Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children.
Li JN; Li Y; Lin JX; Wang LN; Zhang XL; Ouyang J; Chen DB; Chen SQ; Li JX; Luo XQ; Tang YL; Huang LB
Front Immunol; 2023; 14():1280759. PubMed ID: 38045698
[TBL] [Abstract][Full Text] [Related]
15. Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Niyongere S; Sanchez-Petitto G; Masur J; Baer MR; Duong VH; Emadi A
Pharmaceuticals (Basel); 2020 Jun; 13(6):. PubMed ID: 32560218
[TBL] [Abstract][Full Text] [Related]
16. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia.
Gupta S; Casey J; Lasky J
Front Oncol; 2023; 13():1246924. PubMed ID: 38023197
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia.
Kathari YK; An M; Dougherty C; Emadi A
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543121
[TBL] [Abstract][Full Text] [Related]
19. [Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].
Shi YJ; Han Y; Wang Y; Mao DF; Zhang JL; Xi R; Bai H; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):516-519. PubMed ID: 37550212
[No Abstract] [Full Text] [Related]
20. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A; Mikhailova E; Komkov A; Gaskova M; Abasov R; Matveev E; Kazanov M; Mamedov I; Shmitko A; Belova V; Miroshnichenkova A; Illarionova O; Olshanskaya Y; Tsaur G; Verzhbitskaya T; Ponomareva N; Bronin G; Kondratchik K; Fechina L; Diakonova Y; Vavilova L; Myakova N; Novichkova G; Maschan A; Maschan M; Zerkalenkova E; Popov A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
